首页> 美国卫生研究院文献>Canadian Journal of Comparative Medicine >Development and analytic validation of an enzyme-linked immunosorbent assay for the measurement of canine pancreatic lipase immunoreactivity in serum
【2h】

Development and analytic validation of an enzyme-linked immunosorbent assay for the measurement of canine pancreatic lipase immunoreactivity in serum

机译:酶联免疫吸附法测定血清中犬胰脂肪酶免疫反应性的开发及分析验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recently, a radioimmunoassay (RIA) for measurement of canine pancreatic lipase immunoreactivity (cPLI) in serum was developed and validated. However, RIAs require frequent use of radioactive materials. Therefore, the goal of this project was to develop and validate an enzyme-linked immunosorbent assay (ELISA) for cPLI. After purifying cPL, we developed and purified antiserum against cPL in rabbits. The purified antibody was bound to microtitre plates and used to capture antigen. A portion of the purified antibody was biotinylated and used to identify the captured antigen. Streptavidin labelled with horseradish peroxidase and a horseradish peroxidase substrate were used for detection. The assay was validated by determination of sensitivity, working range, linearity, accuracy, precision, and reproducibility. The reference interval for serum cPLI was determined by the central 95th percentile in 74 clinically healthy dogs: 2.2 to 102.1 μg/L. The sensitivity and the upper limit of the working range were 0.1 and 999.2 μg/L, respectively. The ratios of observed to expected values for dilutional parallelism for 6 serum samples ranged from 0.0 to 148.8%; the ratios for spiking recovery for 4 serum samples ranged from 90.4 to 112.6%, assuming 55% recovery of the cPL. Coefficients of variation for intra- and interassay variability for 6 different serum samples were 2.4, 3.4, 4.1, 5.8, 7.4, and 10.0% and 5.9, 7.7, 11.6, 13.9, 23.5, and 46.2%, respectively. We conclude that the ELISA described here is sufficiently sensitive, linear, accurate, precise, and reproducible for clinical application. Evaluation of its clinical usefulness for the diagnosis of exocrine pancreatic disorders in dogs is under way.
机译:最近,开发并验证了用于测定血清中犬胰脂肪酶免疫反应性(cPLI)的放射免疫分析(RIA)。但是,RIA要求经常使用放射性物质。因此,该项目的目标是开发和验证用于cPLI的酶联免疫吸附测定(ELISA)。纯化cPL后,我们开发并纯化了兔抗cPL的抗血清。纯化的抗体与微量滴定板结合,并用于捕获抗原。一部分纯化的抗体被生物素化并用于鉴定捕获的抗原。用辣根过氧化物酶标记的链霉亲和素和辣根过氧化物酶底物进行检测。通过确定灵敏度,工作范围,线性,准确性,精密度和可重复性来验证该测定。血清cPLI的参考间隔由74位临床健康犬的第95个中心百分数确定:2.2至102.1μg/ L。工作范围的灵敏度和上限分别为0.1和999.2μg/ L。 6个血清样品的稀释平行度的观察值与预期值的比率为0.0到148.8%。假设cPL的回收率为55%,则4个血清样品的加标回收率的范围为90.4至112.6%。 6种不同血清样品的批内和批间变异性变异系数分别为2.4%,3.4%,4.1%,5.8%,7.4%和10.0%,以及5.9%,7.7%,11.6%,13.9%,23.5%和46.2%。我们得出的结论是,此处描述的ELISA对临床应用具有足够的敏感性,线性,准确性,精确性和可重复性。目前正在评估其对犬外分泌性胰腺疾病的诊断的临床实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号